Shares in AstraZeneca fell as much as 5.4% before paring losses to trade down 3.2% at about 102 pounds by 0929 GMT, underperforming London's blue-chip FTSE 100 , opens new tab, which rose 0.2%.

AstraZeneca targets $80bn revenue by 2030, ... AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet. Jun. 07, 2025 4:55 AM ET AstraZeneca PLC (AZN) ...

AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but the company has very little information about the case, its CEO said on ...

AstraZeneca entered mainland China in 1993 and is now the largest foreign pharmaceutical company in the country. China is AstraZeneca's third-largest market, according to the company's website.

Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new ...

AstraZeneca has become Britain’s first £200bn company following a 20pc rally in its share price since the start of the year. Shares in the pharmaceutical business rose 1.1pc yesterday to value ...

AstraZeneca (AZN) has joined the legal fight against Medicare drug pricing negotiations, becoming the sixth pharmaceutical company, and first international company, to file suit against US Health ...

AstraZeneca has signed a deal worth up to $247mn with Absci Corporation of the US to design an antibody to fight cancer, the latest tie-up in fast-expanding efforts to use artificial intelligence ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030.

AstraZeneca has launched a new company to allow CROs and fellow Big Pharmas to pay to access its tried-and-tested digital solutions for running clinical trials. The standalone company, called ...

AstraZeneca says the drug could benefit some 2% of the population who cannot mount an effective immune response from COVID-19 vaccines. "We hope to make AZD3152 available as a new prophylactic ...

AstraZeneca joins as the sixth pharma company, and the first non-US company, to file suit against the Biden Administration over Medicare drug pricing.